Congratulations to GE Healthcare for FDA approved DaTscan™

PRINCETON, NJ, (January 14, 2011) /PRNewswire/ — GE Healthcare announced today the US Food and Drug Administration (FDA) has approved DaTscan™ (Ioflupane I 123 Injection), a radiopharmaceutical agent intended for use with single photon emission computed tomography (SPECT) imaging, for the detection of dopamine transporters (DaT) in the brains of adult patients with suspected Parkinsonian syndromes (PS). Click here to read the press release.